A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

Alkermes Inc0 个研究点目标入组 500 人开始时间: 2017年6月30日最近更新: 2023年11月20日

试验速览

暂无简介。

•1. Subject is willing and able to give informed consent/assent as per local requirements.
•2. Subject agrees to use an acceptable method of contraception during the study and until 30 days after any study drug administration, unless surgically sterile or post-menopausal.
•3. Subject has the potential to benefit from the administration of ALKS 3831, in the opinion of the Investigator.
•4. Subject met eligibility criteria and completed the treatment period in one of the following antecedent studies within 7 days: ALK3831-A304, ALK3831-A306, or ALK3831-A307.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 494
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 6

•1. Subject has any finding that in the view of the investigator or medical monitor would compromise the safety of the subject or affect his/her ability to fulfill the protocol visit schedule or visit requirements.
•2. Subject has a positive drug screen for drugs of abuse at study entry.
•3. Subject is currently pregnant, breastfeeding or is planning to become pregnant during the study or within 30 days of the last study drug administration.

发起方